Grace Frank has worked as an editor and reporter for leading American newspapers, including The New York Times, The International Herald Tribune and the Tampa Tribune. She has won numerous journalism awards, including recognition as the best education reporter in Florida (an annual honor given by the statewide teachers' union) and was nominated for a Pulitzer Prize for an investigative series into eye surgeries wrongly conducted outside a clinical trial.
Grace holds a master's degree in international relations from the University of Chicago (attending on a full-tuition fellowship), and a bachelor's degree in political science from Rutgers University–Newark campus.
The U.S. Food and Drug Administration has decided not to fine or otherwise sanction Novartis for manipulated data included in the application that led to Zolgensma‘s approval to treat spinal muscular ... Read more
Eighteen states are now screening newborns for spinal muscular atrophy (SMA), the most recent neuromuscular disease added to a list of serious genetic disorders that infants can be tested ... Read more
With about $18 million expected to be awarded in 2020 for grants supporting research across neuromuscular diseases, the Muscular Dystrophy Association (MDA) continues to be a leader in efforts to better ... Read more
The parents of two babies treated in July with Zolgensma, the first gene therapy approved for spinal muscular atrophy or any neuromuscular disease, are confident they made the right choice ... Read more
The U.S. Food and Drug Administration (FDA) accepted Genentech‘s application requesting approval for risdiplam, its potential oral treatment for all types of spinal muscular atrophy (SMA), and gave it priority ... Read more
AveXis, the company that developed the gene therapy Zolgensma to treat spinal muscular atrophy (SMA), knew of “data manipulation issues” that led to inaccuracies in its application to the ... Read more
Pin It on Pinterest